Vinati Organics eyes ATBS recovery as raw-material costs pressure margins

Investment View and Key Thesis

In its July 31, 2026 result update, Deven Choksey Research retained its ACCUMULATE rating on Vinati Organics Ltd. The broker believes the company is entering a volume-led growth phase after a prolonged period of pricing-led earnings.

The positive case rests on Vinati Organics' leadership in ATBS, its expanding antioxidants portfolio and a healthy balance sheet. Management remains confident of around 15 per cent volume growth in FY27 and expects a stronger H2 FY27 as industrial demand improves, ATBS demand recovers and capacity utilisation rises.

Q1 FY27 Performance: Strong Revenue Growth, Margin Pressure

Vinati Organics reported Q1 FY27 revenue of Rs 6,959 million, up 28.4 per cent year on year and 15.2 per cent quarter on quarter. Growth was supported principally by strong exports, helped by rupee depreciation, and healthy antioxidant volume growth.

However, the report highlights limited pricing power amid raw-material inflation. Total expenditure rose 37.4 per cent year on year, while the cost of materials consumed increased 35.2 per cent year on year to Rs 3,806 million. Higher input costs could be passed through only selectively across products.

As a result, Q1 FY27 EBITDA increased only 6.8 per cent year on year to Rs 1,705 million and was broadly flat sequentially. EBITDA margin contracted to 24.5 per cent from 29.5 per cent in Q1 FY26 and 28.2 per cent in Q4 FY26.

Profit after tax rose 4.5 per cent year on year to Rs 1,089 million but declined 12.1 per cent sequentially. PAT margin was 15.6 per cent versus 19.2 per cent a year earlier. The report does not state whether the quarterly result beat or missed broker estimates.

Operating Outlook and Key Monitorables

Management has reiterated EBITDA margin guidance of 26-27 per cent, subject to raw-material prices and product mix. Key operating monitorables include the anticipated H2 FY27 ATBS-volume recovery, commercialisation of new specialty products and execution at the Veeral Organics facility.

Following re-engineering, the Veeral Organics facility is expected to be commissioned by December 2026, although it is unlikely to make a material revenue contribution before then.

Broker Estimates

Deven Choksey Research forecasts revenue, EBITDA and PAT CAGRs of 13.7 per cent, 8.2 per cent and 7.0 per cent, respectively, over FY26-FY28.

Valuation and Target Price

The broker notes that the stock trades at 26.5 times FY28E earnings and values Vinati Organics at 29 times FY28E EPS. This produces a target price of Rs 1,420, implying upside of 9.2 per cent from the stated CMP of Rs 1,300.

Principal Risks

• Crude-linked raw-material price volatility and an inability to pass cost increases through promptly.
• A slower-than-expected recovery in global industrial demand and ATBS volumes.
• Delays in commissioning Veeral Organics or commercialising new specialty chemicals.